Skip to main content
Quest Diagnostics

Solid Tumor

Solid tumor decision diagnostics to navigate rapid shifts in cancer care

The diagnosis and treatment of cancer is progressing rapidly—yet implementing these advancements can tax a health system’s limited resources. To help you stay ahead, Quest Advanced® offers a comprehensive portfolio of molecular testing and pathology solutions and services for solid tumors.

With advanced testing, medical expertise, technical solutions, and customer service, we can empower you to transform cancer care and deliver personalized insights to help drive actionable treatments for each individual patient.

Your single-source solution for solid tumor diagnostics

Testing needs are met with a comprehensive menu that spans basic to complex molecular tests, with integrated clinical services and exceptional turnaround time

Treatment plans are supported through direct access to Quest oncology MDs, PhDs, and world-renowned pathologists for consultation and results interpretation

Patients benefit from pan-cancer and disease-targeted solutions that can help clinicians take action to improve their treatment and help determine eligibility for clinical trials

Patients’ results are delivered in comprehensive, easy-to-understand reports that match the genetic characteristics of their tumor

Innovative solid tumor molecular diagnostics

Our solutions provide choice for your clinicians, whether by aligning with standard of care and clinical trial options, or by helping them navigate new and emerging therapies beyond current standards of care.

Provides a comprehensive molecular profile that includes 49 clinically actionable genes associated with a broad spectrum of cancers. Includes: microsatellite instability (MSI), tumor mutational burden (TMB), and RNA for fusions.

View test

Provides a comprehensive molecular profile that includes 500+ genes associated with a broad spectrum of cancers. This panel contains clinically actionable genes as well as emerging genes. Includes: microsatellite instability (MSI), tumor mutational burden (TMB), and RNA for fusions.

View test

Next-generation sequencing panels for specific cancers, including lung, colon, and melanoma

ColonSEQ Panel
ColonSEQPlus Panel
MelanomaSEQ® Panel
MelanomaSEQPlus® Panel
LungSEQ® Panel

Identifying biomarkers is critical

Biomarkers are vital to understanding the full genetic makeup of a patient’s tumor, providing the information your clinicians need to make an accurate diagnosis and initiate appropriate cancer treatment.

Solid tumors (pan-cancer biomarkers): NTRK, TMB, MSI*
*NTRK, neurotrophic tyrosine receptor kinase gene fusion; TMB, tumor mutational burden; MSI, microsatellite instability.

Expert analysis at every stage of care

Our medical experts and pathologists are available for consultation on every case to uncover answers for patients.

600+ MDs, PhDs, and world-renowned pathologists are available for professional consultations

Connecting patients and physicians to clinical trial sponsors and clinical research organizations

Medical science liaisons to share key medical and scientific information to keep you up-to-date

Highly specialized competencies in dermatopathology and pathology via Dermpath Diagnostics® and AmeriPath®

Specialty support for block retrieval

We offer a comprehensive block retrieval program for when the sample is not on hand:

  • Block procurement for new solid tumor orders
  • Case management support, including consultation on acceptable sample types
  • Return block to pathology after testing is complete
  • Customer service support, including specimen tracking and supply ordering

Contact our team 8:00 AM to 9:00 PM EST:

1.833.733.1441 (phone)

1.207.536.6675 (fax)

Contact us

Discover how solid tumor testing can help keep you at the forefront of rapid advancements in cancer care.

Get in touch today.

 

631

* indicates required

About our tests

Visit our ThoughtLab for hospitals and health systems resources

Pathology & Laboratory Medicine
Article
The rise of genetic testing offers a chance to improve clinical quality and service—and control costs
Pathology & Laboratory Medicine
Article
The growing value of genetic diagnostic expertise to health systems
Pathology & Laboratory Medicine
Article
Balancing the desire for quick AML results with precision genetic testing
Management & Operations
Article
Why genetic testing for women must become more accessible and affordable
View All Articles

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.